New Therapies and Mechanisms of HER2-positive Breast Cancer and Beyond

Pathology Cancer Center Grand Rounds

Thursday, February 25, 2021 at 12:00 PM


Grand Round starts in:

Online Streaming
February 25th, 2021
1.00 AMA PRA Category 1 Credit Hours

Description

In this seminar, I will describe my lab's recent advances in three areas. First, I will focus on the mechanisms of acquired resistance to an HSP90 inhibitor drug, Ganetespib, in HER2-positive breast cancer. Second, I will describe how p63, an epithelial gatekeeper gene, regulates pregnancy-associated HER2-positive breast cancer via its tumor-initiating cells PIMECs (pregnancy-induced mammary epithelial cells). Finally, I will give an overview of our novel discoveries of how p63 regulates normal adult skin homeostasis.

Dates and Times

Start: 2/25/2021 12:00 PM
End: 2/25/2021 1:00 PM

Objectives

1. Learn about HSP90 inhibitor drugs for breast cancer.
2. Learn about pregnancy-associated HER2-positive breast cancer and its regulation.
3. Learn about the regulation of adult skin homeostasis.

Speakers

  • Dr. Evguenia Alexandrova
    • New Therapies and Mechanisms of HER2-positive Breast Cancer and Beyond

Accreditation

The School of Medicine, State University of New York at Stony Brook, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The School of Medicine, State University of New York at Stony Brook designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit(s) . Physicians should only claim the credit commensurate with the extent of their participation in the activity.

Give us a call
(631) 444-2094
Office of Continuing Medical Education
Renaissance School of Medicine at Stony Brook University
HSC, Level 2, Room 142
Stony Brook, New York 11794-8222